# Determining the Lymphokine Activated Killer (LAK) Cytotoxicity Present in Patients Undergoing Interleukin-2 Therapy

> **NCT01068470** · — · TERMINATED · sponsor: **Loma Linda University** · enrollment: 11 (actual)

## Conditions studied

- Melanoma
- Kidney Cancer

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT01068470
- **Lead sponsor:** Loma Linda University
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** TERMINATED
- **Start date:** 2009-11
- **Primary completion:** 2010-12
- **Final completion:** 2012-03
- **Target enrollment:** 11 (ACTUAL)
- **Why stopped:** PI left the institution
- **Last updated:** 2014-05-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01068470

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01068470, "Determining the Lymphokine Activated Killer (LAK) Cytotoxicity Present in Patients Undergoing Interleukin-2 Therapy". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01068470. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*